<SEC-DOCUMENT>0001104659-20-093904.txt : 20200812
<SEC-HEADER>0001104659-20-093904.hdr.sgml : 20200812
<ACCEPTANCE-DATETIME>20200812161618
ACCESSION NUMBER:		0001104659-20-093904
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200812
DATE AS OF CHANGE:		20200812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		201095667

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2027384d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): August 12, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>CYCLACEL
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices
and zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-indent: -17.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">Securities registered pursuant
to Section&nbsp;12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Common Stock, par value $0.001 per share</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Preferred Stock, $0.001 par value</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">CYCCP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 24.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 2.02</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations
and Financial Condition.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated August 12, 2020, announcing certain financial
results for the second quarter ended June 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will conduct a conference call
to review its financial results on August 12, 2020, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements
and Exhibits.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 50pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><A HREF="tm2027384d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="tm2027384d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release announcing financial results for the second quarter ended June 30, 2020, dated August 12, 2020.</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance,</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 12, 2020&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2027384d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-underline-style: double"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="text-transform: capitalize; text-underline-style: double"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="text-transform: capitalize; text-underline-style: double"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;<IMG SRC="image_002.jpg" ALT="" STYLE="height: 48.45pt; width: 130.1pt"></TD>
    <TD STYLE="width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                           <P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">Cyclacel Pharmaceuticals, Inc.</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="text-transform: capitalize; text-underline-style: double"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase; text-underline-style: double"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase; text-underline-style: double"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 19.5pt; width: 429pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Pharmaceuticals Reports SECOND Quarter 2020 Financial Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>- Conference
Call Scheduled August 12, 2020 at 4:30 p.m. ET -</I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 174.25pt; text-align: center; text-indent: -2.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Berkeley Heights, NJ, August 12,
2020</B> - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing innovative medicines based on cancer cell biology, today reported its financial results for the second quarter
2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel's novel CDK2/9 inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company's net loss applicable to
common shareholders for the three months ended June 30, 2020 was $2.2 million. As of June 30, 2020, cash and cash equivalents totaled
$25.3 million. Based on current spending, the Company estimates it has sufficient resources to fund planned operations, including
research and development, through the end of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;We believe fadraciclib is establishing
a leadership position among MCL1 suppressing compounds in development. Our recent, peer-reviewed publication elaborates <FONT STYLE="color: #2E2E2E; background-color: white">the
mechanistic rationale for fadraciclib as an anti-cancer therapy signifying the benefits of inhibiting CDK2 and CDK9, two complementary
cancer pathways</FONT>,&rdquo; said Spiro Rombotis, President and Chief Executive Officer. &ldquo;We continue to be encouraged
by observations of deep partial response and prolonged stable disease with tumor shrinkage as an intravenously administered monotherapy
in patients with advanced solid tumors and antileukemic activity in combination with venetoclax. <FONT STYLE="color: #2E2E2E; background-color: white">In
parallel with evaluating fadraciclib in certain leukemias, we are executing a precision medicine strategy to evaluate the compound
in patients with solid tumors with study enrollment expected to begin by the first quarter of 2021. As the </FONT>global pandemic
continues to unfold, our priorities are to ensure patient and employee safety and support efforts to stem COVID-19 disease as part
of our corporate social responsibility. Despite the challenges we remain committed to our strategy of building an innovative pipeline
addressing the rising problem of cancer resistance and achieving our clinical milestones to drive shareholder value.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Corporate Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2E2E2E">Announced publication of
a peer-reviewed study of fadraciclib, in <I>PLOS ONE.</I> The publication, authored by scientists from </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Cyclacel
<FONT STYLE="color: #2E2E2E; background-color: white">and </FONT>The Institute of Cancer Research<FONT STYLE="color: #2E2E2E; background-color: white">,
</FONT>London<FONT STYLE="color: #2E2E2E; background-color: white">, describes the discovery of fadraciclib and shows its ability
to target CDK2 and CDK9, leading to broad therapeutic potential.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-01 Phase 1 part 2 single agent i.v. &ndash;</B> As previously
reported a heavily pretreated patient with MCL1 amplified endometrial cancer achieved a radiographically confirmed partial response
(PR) after a month and a half on fadraciclib at 213mg. This patient continues on therapy for more than a year and reduction in
her target tumor lesions is 83%. An additional patient with cyclin E amplified ovarian cancer achieved stable disease with 29%
tumor shrinkage after approximately four months at 213mg. We have submitted data for publication at a cancer conference later in
the year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Based on data thus far, we are designing a Phase 1/2 precision medicine
study to further evaluate fadraciclib as monotherapy and in combinations in patients with advanced solid tumors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-01 Phase 1 part 3 single agent p.o. -</B> Initial data from
an oral capsule formulation of fadraciclib given once daily to four patients with advanced solid tumors demonstrated a predictable
pharmacokinetic profile closely overlapping the intravenous form with encouraging exposure levels.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-03 Phase 1 fadraciclib i.v. and venetoclax p.o. in AML/MDS
-</B> We have dosed 11 heavily pretreated patients with relapsed/refractory (R/R) AML in five dose levels up to 200 mg/m<SUP>2</SUP>
of fadraciclib in combination with venetoclax. Evidence of anticancer activity has been observed in four out of eleven patients
treated. Preclinical data in AML suggest that targeting both MCL1 and BCL2 may be more beneficial than inhibiting either protein
alone.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC065-02 Phase 1 fadraciclib i.v. and venetoclax p.o. in CLL -</B>
We have dosed 5 patients with R/R CLL in four dose levels up to 150 mg/m<SUP>2</SUP> of fadraciclib in combination with venetoclax.
Evidence of anticancer activity has been observed in two patients who achieved MRD negativity on the combination. Preclinical data
suggest that targeting both BCL2 and MCL1 in CLL may be more beneficial than single agent treatment in this setting as well.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC682-11 Phase 1 part 2 sapacitabine p.o. and venetoclax p.o.
-</B> We have enrolled 12 patients in a dose escalation study in our DNA Damage Response (DDR) program evaluating an oral combination
of sapacitabine and venetoclax in patients with R/R AML/MDS. Two patients, previously treated with combination therapies including
hypomethylating agents, have achieved 5 and 6 cycles of treatment respectively. Sapacitabine is a nucleoside analogue that is active
in AML and MDS R/R to prior therapy such as cytarabine or hypomethylating agents. Preclinical data demonstrated synergy of sapacitabine
with BCL2 inhibition, which may offer an effective, oral treatment regimen for patients who have failed front-line therapy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CYC140-01 Phase 1 CYC140 i.v. -</B> We have enrolled 6 patients
in our first-in-human, dose escalation study evaluating CYC140 in patients with advanced leukemias. CYC140 is a small molecule,
selective polo-like-kinase 1 (PLK1) inhibitor that has demonstrated potent and selective target inhibition and high activity in
xenograft models of human cancers. In addition to hematological malignancies we are evaluating studies of CYC140 in solid tumors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">More information on our clinical trials can be found here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Key Business Objectives</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report updated fadraciclib Phase 1 safety and efficacy data with frequent
i.v. dosing schedule in patients with advanced solid cancers;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report initial safety and PK data from Phase 1 study of fadraciclib
oral formulation;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Treat first patient in fadraciclib Phase 1/2 precision medicine study;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report initial data from fadraciclib-venetoclax Phase 1 study in R/R
AML/MDS &amp; CLL;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report initial data from sapacitabine-venetoclax Phase 1 study in
R/R AML/MDS;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report initial data from CYC140 Phase 1 first-in-human study in R/R
leukemias; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 12.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 9.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report data from Phase 1b/2 sapacitabine-olaparib
IST in BRCA mutant metastatic breast cancer when reported by the investigators.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.7pt 0pt 0"><B>Financial Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">As of June 30, 2020, cash and cash
equivalents totaled $25.3 million, compared to $11.9 million as of December 31, 2019. The increase of $13.4 million was primarily
due to net proceeds of $18.3 million from an equity financing in April 2020 and net cash used in operating activities of $4.7 million.
There were no revenues for each of the three months ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $1.2 million for each
of the three months ended June 30, 2020 and 2019. Research and development expenses relating to transcriptional regulation increased
by approximately $0.2 million for the three&nbsp;months ended June 30, 2020 as we continue to progress the clinical evaluation
of fadraciclib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">General and administrative expenses
for the three months ended June 30, 2020 were $1.3 million, compared to $1.2 million for the same period of the previous year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Total other income, net, for the three
months ended June 30, 2020 was $20,000, compared to $0.2 million for the same period of the previous year. The decrease of approximately
$0.2 million for the three months ended June 30, 2020 is primarily related to income received under an Asset Purchase Agreement
with Thermo Fisher Scientific Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">United Kingdom research &amp; development
tax credits were $0.3 million for each of the three months ended June 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Net loss for the three months ended
June 30, 2020 was $2.2 million compared to $1.8 million for the same period in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company <FONT STYLE="color: #231F20">estimates
that cash resources </FONT>of $25.3 million as of June 30, 2020 <FONT STYLE="color: #231F20">will fund currently planned programs
through 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Conference call information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US/Canada call: (877) 493-9121 / international call: (973) 582-2750&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US/Canada archive: (800) 585-8367 / international archive: (404)
537-3406&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Code for live and archived conference call is 2477369.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For the live and archived webcast,
please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90
days and the audio replay for 7 days.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>About Cyclacel Pharmaceuticals,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and DNA damage
response biology. The transcriptional regulation program is evaluating fadraciclib as a single agent in solid tumors and in combination
with venetoclax in patients with relapsed or refractory AML/MDS and CLL. The DNA damage response program is evaluating an oral
combination of sapacitabine and venetoclax in patients with relapsed or refractory AML/MDS. An investigator-sponsored trial (IST)
is evaluating an oral combination of sapacitabine and olaparib in patients with BRCA mutant breast cancer. The anti-mitotic program
is evaluating CYC140, a PLK1 inhibitor, in advanced leukemias/MDS patients. Cyclacel's strategy is to build a diversified biopharmaceutical
business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit
www.cyclacel.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>Forward-looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="color: Black">This news
release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results expressed or implied by such forward-looking statements.
Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization
of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially
include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety
and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval
to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the
risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product
candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot;
&quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot;
&quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
&quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #2E2E2E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #2E2E2E">Company:&nbsp; &nbsp; &nbsp; &nbsp;
&nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Paul McBarron, (908) 517-7330,&nbsp;</FONT>pmcbarron@cyclacel.com<FONT STYLE="color: #2E2E2E"><BR>
<BR>
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #2E2E2E">Investor Relations:&nbsp; Russo
Partners LLC, </FONT>Jan Medina, (646) 942-5632, Jan.Medina@russopartnersllc.com&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&copy; Copyright 2020 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0">Three Months Ended</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0">June 30,</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-indent: 0">2019</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-indent: 0">2020</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">Revenues:</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Total revenues</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">-</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">-</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Operating expenses:</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; width: 74%; text-align: left; text-indent: 0">&nbsp;Research and development</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; width: 10%; font-size: 10pt; text-align: right; text-indent: 0">1,153</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; width: 10%; font-size: 10pt; text-align: right; text-indent: 0">1,163</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">&nbsp;General and administrative</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">1,184</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">1,309</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Total operating expenses</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">2,337</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">2,472</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Operating loss</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(2,337</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(2,472</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Other income (expense):</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">&nbsp;Foreign exchange gains (losses)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">21</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(2</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">&nbsp;Interest income</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">56</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">4</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">&nbsp;Other income, net</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">170</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">18</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.25in; text-align: left; text-indent: 0">&nbsp;Total other income (expense), net</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">247</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">20</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Loss before taxes</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(2,090</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(2,452</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Income tax benefit</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">307</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">286</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Net loss</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(1,783</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">(2,166</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">(50</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">(50</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Net loss applicable to common shareholders</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">(1,833</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">(2,216</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">Basic and diluted earnings per common share:</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Net loss per share &ndash; basic and diluted</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">(2.13</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">(0.58</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">Weighted average common shares outstanding</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">859,998</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">3,850,228</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(In $000s, except share, per share, and
liquidation preference amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0">December 31,</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; text-indent: 0">June 30,</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-indent: 0">2019</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; text-indent: 0">2020</TD><TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-indent: 0">ASSETS</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Current assets:</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; width: 74%; text-align: left; text-indent: 0">Cash and cash equivalents</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; width: 10%; font-size: 10pt; text-align: right; text-indent: 0">11,885</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; width: 10%; font-size: 10pt; text-align: right; text-indent: 0">25,342</TD><TD STYLE="padding: 0; width: 1%; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">Prepaid expenses and other current assets</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">2,132</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">2,591</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.25in; text-align: left; text-indent: 0">Total current assets</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">14,017</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">27,933</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">Property and equipment, net </TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">27</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">20</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">Right-of-use lease asset</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">1,264</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">1,218</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.25in; text-align: left; text-indent: 0">Total assets</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">15,308</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">29,171</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; font-weight: bold; text-align: left; text-indent: 0">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Current liabilities:</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">Accounts payable</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">890</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">342</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.125in; text-align: left; text-indent: 0">Accrued and other current liabilities</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">1,530</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">1,170</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.25in; text-align: left; text-indent: 0">Total current liabilities</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">2,420</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">1,512</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Lease liability</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">1,191</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">1,081</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Other liabilities</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">-</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">-</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.25in; text-align: left; text-indent: 0">Total liabilities</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">3,611</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">2,593</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">Stockholders&rsquo; equity</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">11,697</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; text-indent: 0">26,578</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 0.25in; text-align: left; text-indent: 0">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">15,308</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; text-indent: 0">$</TD><TD STYLE="padding: 0; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; text-indent: 0">29,171</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: right; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; font-size: 10pt; text-align: left; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOURCE: Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ 4H# 2(  A$! Q$!_\0
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MK_(UM6'CKQ!8[1]L^T1K_!<+OS]6^]^M;O\ PC?@N_1C9:\8'/W1+*H /T8
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M **** "BBB@ HHHH **** "BBB@ HHHH *S]:UBVT/3);VY/"\(F<%V[*/\
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MWZN<EOY>]%/V5*7+1CSRZO\ X/\ D%7V]>//B)^SAT7_  .OS^XXZU\):_>
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MY?#3_/\ X>[^1S'Q%\1&RLUTBV;$URN9F'58^F/QY_ 'UJEX(\*006RZ]JH
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M$0J4%-S2U?4XCX??#.P^'KZFUG?W-T;YD_UP V(N[:..I^8Y/Y <Y[BBBH-
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MG_PF^NS:9_PC]WI_EVS3^;,^X'#*NW[HY^;/X4GCKXL6_@CQ19Z)+I,MV]U
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MP1\9=&\9V4B26]T5>=8F5F)0".50.@S&RX/J375_\,X>$?\ H)ZY_P!_HO\
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M3^ O@;4'+0VMYIY.2?LER<$Y]'# ?AQ3M%^!7@W1;^WO52_NYK=Q)&;BXX#
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MU_'?\R2"Y@NHQ);SQS(>C1N&!_$5+7):GX,\/QQ>8FG!6)[2N!T/;=7""VC
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X!/(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"M?7]OIUL9[ERL><< G)]*QO^$T
MTS?M\NYQ_>V#'\Z7QE_R U_Z[+_(U#X?6!O"4HN IBS(6W=*74QE*7/RHWK*
M_MM0@\ZUE$B9P>Q!]"*LUQ'@AI/M]RHSY1B!;ZYX_K7;T(NG+FC<****9855
MO]0MM-M_/NG*H6VC ))/I^E6JYOQM_R!H?\ KX7_ -!:ADSERQ;0X>--,+X\
MNY _O;!C^=;-E?VVH0>=:RB1.A[$'T([5B:"D#^#R+@*8L2%MW3J>:S?!'F_
M;KK&?)\L;O\ >SQ^F:5S*,Y75^IVU%%%,W"BBB@"IJ.HP:7:BXN Y0L%^09.
M3_\ JK)_X3+2_P"[<?\ ? _QH\9?\@-?^NR_R-9_AF?28]**WK6@E\T_ZT+G
M&!ZTKZF,IRY^5,ZVWF6YMHITSLD0.N>N",U)34"JBA  @ "@= *=3-@HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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0G//YT44QJ"6Q/11104?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
